Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Pan-Cancer Metabolic Signature Predicts Co-Dependency on Glutaminase and De Novo Glutathione Synthesis Linked to a High-Mesenchymal Cell State.

Daemen A, Liu B, Song K, Kwong M, Gao M, Hong R, Nannini M, Peterson D, Liederer BM, de la Cruz C, Sangaraju D, Jaochico A, Zhao X, Sandoval W, Hunsaker T, Firestein R, Latham S, Sampath D, Evangelista M, Hatzivassiliou G.

Cell Metab. 2018 Jun 16. pii: S1550-4131(18)30385-1. doi: 10.1016/j.cmet.2018.06.003. [Epub ahead of print]

PMID:
30043751
2.

Aminoisoxazoles as Potent Inhibitors of Tryptophan 2,3-Dioxygenase 2 (TDO2).

Pei Z, Mendonca R, Gazzard L, Pastor R, Goon L, Gustafson A, VanderPorten E, Hatzivassiliou G, Dement K, Cass R, Yuen PW, Zhang Y, Wu G, Lin X, Liu Y, Sellers BD.

ACS Med Chem Lett. 2018 Apr 2;9(5):417-421. doi: 10.1021/acsmedchemlett.7b00427. eCollection 2018 May 10.

PMID:
29795752
3.

Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease.

Soomro I, Sun Y, Li Z, Diggs L, Hatzivassiliou G, Thomas AG, Rais R, Slusher BS, Somlo S, Skolnik EY.

Nephrol Dial Transplant. 2018 Feb 5. doi: 10.1093/ndt/gfx349. [Epub ahead of print]

PMID:
29420817
4.

GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP).

Romero FA, Murray J, Lai KW, Tsui V, Albrecht BK, An L, Beresini MH, de Leon Boenig G, Bronner SM, Chan EW, Chen KX, Chen Z, Choo EF, Clagg K, Clark K, Crawford TD, Cyr P, de Almeida Nagata D, Gascoigne KE, Grogan JL, Hatzivassiliou G, Huang W, Hunsaker TL, Kaufman S, Koenig SG, Li R, Li Y, Liang X, Liao J, Liu W, Ly J, Maher J, Masui C, Merchant M, Ran Y, Taylor AM, Wai J, Wang F, Wei X, Yu D, Zhu BY, Zhu X, Magnuson S.

J Med Chem. 2017 Nov 22;60(22):9162-9183. doi: 10.1021/acs.jmedchem.7b00796. Epub 2017 Sep 21.

PMID:
28892380
5.

Role of the E3 ubiquitin ligase RNF157 as a novel downstream effector linking PI3K and MAPK signaling pathways to the cell cycle.

Dogan T, Gnad F, Chan J, Phu L, Young A, Chen MJ, Doll S, Stokes MP, Belvin M, Friedman LS, Kirkpatrick DS, Hoeflich KP, Hatzivassiliou G.

J Biol Chem. 2017 Sep 1;292(35):14311-14324. doi: 10.1074/jbc.M117.792754. Epub 2017 Jun 27.

6.

Preparation and evaluation of L- and D-5-[18F]fluorotryptophan as PET imaging probes for indoleamine and tryptophan 2,3-dioxygenases.

Tang T, Gill HS, Ogasawara A, Tinianow JN, Vanderbilt AN, Williams SP, Hatzivassiliou G, White S, Sandoval W, DeMent K, Wong M, Marik J.

Nucl Med Biol. 2017 Aug;51:10-17. doi: 10.1016/j.nucmedbio.2017.05.001. Epub 2017 May 5.

PMID:
28511073
7.

Metabolic Response to NAD Depletion across Cell Lines Is Highly Variable.

Xiao Y, Kwong M, Daemen A, Belvin M, Liang X, Hatzivassiliou G, O'Brien T.

PLoS One. 2016 Oct 6;11(10):e0164166. doi: 10.1371/journal.pone.0164166. eCollection 2016.

8.

Proline Starvation Induces Unresolved ER Stress and Hinders mTORC1-Dependent Tumorigenesis.

Sahu N, Dela Cruz D, Gao M, Sandoval W, Haverty PM, Liu J, Stephan JP, Haley B, Classon M, Hatzivassiliou G, Settleman J.

Cell Metab. 2016 Nov 8;24(5):753-761. doi: 10.1016/j.cmet.2016.08.008. Epub 2016 Sep 8.

9.

Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition.

Boudreau A, Purkey HE, Hitz A, Robarge K, Peterson D, Labadie S, Kwong M, Hong R, Gao M, Del Nagro C, Pusapati R, Ma S, Salphati L, Pang J, Zhou A, Lai T, Li Y, Chen Z, Wei B, Yen I, Sideris S, McCleland M, Firestein R, Corson L, Vanderbilt A, Williams S, Daemen A, Belvin M, Eigenbrot C, Jackson PK, Malek S, Hatzivassiliou G, Sampath D, Evangelista M, O'Brien T.

Nat Chem Biol. 2016 Oct;12(10):779-86. doi: 10.1038/nchembio.2143. Epub 2016 Aug 1.

PMID:
27479743
10.

Quantitative phosphoproteomic analysis of the PI3K-regulated signaling network.

Gnad F, Wallin J, Edgar K, Doll S, Arnott D, Robillard L, Kirkpatrick DS, Stokes MP, Vijapurkar U, Hatzivassiliou G, Friedman LS, Belvin M.

Proteomics. 2016 Jul;16(14):1992-7. doi: 10.1002/pmic.201600118. Epub 2016 Jul 8.

PMID:
27282143
11.

Phosphoproteome analysis of the MAPK pathway reveals previously undetected feedback mechanisms.

Gnad F, Doll S, Song K, Stokes MP, Moffat J, Liu B, Arnott D, Wallin J, Friedman LS, Hatzivassiliou G, Belvin M.

Proteomics. 2016 Jul;16(14):1998-2004. doi: 10.1002/pmic.201600119.

PMID:
27273156
12.

Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition.

Ghosh S, Taylor A, Chin M, Huang HR, Conery AR, Mertz JA, Salmeron A, Dakle PJ, Mele D, Cote A, Jayaram H, Setser JW, Poy F, Hatzivassiliou G, DeAlmeida-Nagata D, Sandy P, Hatton C, Romero FA, Chiang E, Reimer T, Crawford T, Pardo E, Watson VG, Tsui V, Cochran AG, Zawadzke L, Harmange JC, Audia JE, Bryant BM, Cummings RT, Magnuson SR, Grogan JL, Bellon SF, Albrecht BK, Sims RJ 3rd, Lora JM.

J Biol Chem. 2016 Jun 17;291(25):13014-27. doi: 10.1074/jbc.M115.708560. Epub 2016 Apr 7.

13.

mTORC1-Dependent Metabolic Reprogramming Underlies Escape from Glycolysis Addiction in Cancer Cells.

Pusapati RV, Daemen A, Wilson C, Sandoval W, Gao M, Haley B, Baudy AR, Hatzivassiliou G, Evangelista M, Settleman J.

Cancer Cell. 2016 Apr 11;29(4):548-562. doi: 10.1016/j.ccell.2016.02.018. Epub 2016 Mar 24.

14.

Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2.

Foster SA, Whalen DM, Özen A, Wongchenko MJ, Yin J, Yen I, Schaefer G, Mayfield JD, Chmielecki J, Stephens PJ, Albacker LA, Yan Y, Song K, Hatzivassiliou G, Eigenbrot C, Yu C, Shaw AS, Manning G, Skelton NJ, Hymowitz SG, Malek S.

Cancer Cell. 2016 Apr 11;29(4):477-493. doi: 10.1016/j.ccell.2016.02.010. Epub 2016 Mar 17.

15.

Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors.

Daemen A, Peterson D, Sahu N, McCord R, Du X, Liu B, Kowanetz K, Hong R, Moffat J, Gao M, Boudreau A, Mroue R, Corson L, O'Brien T, Qing J, Sampath D, Merchant M, Yauch R, Manning G, Settleman J, Hatzivassiliou G, Evangelista M.

Proc Natl Acad Sci U S A. 2015 Aug 11;112(32):E4410-7. doi: 10.1073/pnas.1501605112. Epub 2015 Jul 27.

16.

Metabolic and transcriptional profiling reveals pyruvate dehydrogenase kinase 4 as a mediator of epithelial-mesenchymal transition and drug resistance in tumor cells.

Sun Y, Daemen A, Hatzivassiliou G, Arnott D, Wilson C, Zhuang G, Gao M, Liu P, Boudreau A, Johnson L, Settleman J.

Cancer Metab. 2014 Nov 3;2(1):20. doi: 10.1186/2049-3002-2-20. eCollection 2014.

17.

Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H glioma.

Chen R, Nishimura MC, Kharbanda S, Peale F, Deng Y, Daemen A, Forrest WF, Kwong M, Hedehus M, Hatzivassiliou G, Friedman LS, Phillips HS.

Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):14217-22. doi: 10.1073/pnas.1409653111. Epub 2014 Sep 15.

18.

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.

Hatzivassiliou G, Haling JR, Chen H, Song K, Price S, Heald R, Hewitt JF, Zak M, Peck A, Orr C, Merchant M, Hoeflich KP, Chan J, Luoh SM, Anderson DJ, Ludlam MJ, Wiesmann C, Ultsch M, Friedman LS, Malek S, Belvin M.

Nature. 2013 Sep 12;501(7466):232-6. doi: 10.1038/nature12441. Epub 2013 Aug 11. Erratum in: Nature. 2013 Oct 10;502(7470):258.

PMID:
23934108
19.

An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancer.

McCleland ML, Adler AS, Shang Y, Hunsaker T, Truong T, Peterson D, Torres E, Li L, Haley B, Stephan JP, Belvin M, Hatzivassiliou G, Blackwood EM, Corson L, Evangelista M, Zha J, Firestein R.

Cancer Res. 2012 Nov 15;72(22):5812-23. doi: 10.1158/0008-5472.CAN-12-1098. Epub 2012 Nov 8.

20.

ERK inhibition overcomes acquired resistance to MEK inhibitors.

Hatzivassiliou G, Liu B, O'Brien C, Spoerke JM, Hoeflich KP, Haverty PM, Soriano R, Forrest WF, Heldens S, Chen H, Toy K, Ha C, Zhou W, Song K, Friedman LS, Amler LC, Hampton GM, Moffat J, Belvin M, Lackner MR.

Mol Cancer Ther. 2012 May;11(5):1143-54. doi: 10.1158/1535-7163.MCT-11-1010. Epub 2012 Mar 8.

21.

Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties.

Mathieu S, Gradl SN, Ren L, Wen Z, Aliagas I, Gunzner-Toste J, Lee W, Pulk R, Zhao G, Alicke B, Boggs JW, Buckmelter AJ, Choo EF, Dinkel V, Gloor SL, Gould SE, Hansen JD, Hastings G, Hatzivassiliou G, Laird ER, Moreno D, Ran Y, Voegtli WC, Wenglowsky S, Grina J, Rudolph J.

J Med Chem. 2012 Mar 22;55(6):2869-81. doi: 10.1021/jm300016v. Epub 2012 Feb 29.

PMID:
22335519
22.

Live-cell microscopy reveals small molecule inhibitor effects on MAPK pathway dynamics.

Anderson DJ, Durieux JK, Song K, Alvarado R, Jackson PK, Hatzivassiliou G, Ludlam MJ.

PLoS One. 2011;6(8):e22607. doi: 10.1371/journal.pone.0022607. Epub 2011 Aug 4.

23.

Pyrazolopyridine Inhibitors of B-Raf(V600E). Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors.

Wenglowsky S, Ren L, Ahrendt KA, Laird ER, Aliagas I, Alicke B, Buckmelter AJ, Choo EF, Dinkel V, Feng B, Gloor SL, Gould SE, Gross S, Gunzner-Toste J, Hansen JD, Hatzivassiliou G, Liu B, Malesky K, Mathieu S, Newhouse B, Raddatz NJ, Ran Y, Rana S, Randolph N, Risom T, Rudolph J, Savage S, Selby LT, Shrag M, Song K, Sturgis HL, Voegtli WC, Wen Z, Willis BS, Woessner RD, Wu WI, Young WB, Grina J.

ACS Med Chem Lett. 2011 Mar 8;2(5):342-7. doi: 10.1021/ml200025q. eCollection 2011 May 12.

24.

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.

Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S.

Nature. 2010 Mar 18;464(7287):431-5. doi: 10.1038/nature08833. Epub 2010 Feb 3.

PMID:
20130576
25.

ATP-citrate lyase links cellular metabolism to histone acetylation.

Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR, Thompson CB.

Science. 2009 May 22;324(5930):1076-80. doi: 10.1126/science.1164097.

26.

PERK-dependent regulation of lipogenesis during mouse mammary gland development and adipocyte differentiation.

Bobrovnikova-Marjon E, Hatzivassiliou G, Grigoriadou C, Romero M, Cavener DR, Thompson CB, Diehl JA.

Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16314-9. doi: 10.1073/pnas.0808517105. Epub 2008 Oct 13.

27.

The biology of cancer: metabolic reprogramming fuels cell growth and proliferation.

DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB.

Cell Metab. 2008 Jan;7(1):11-20. doi: 10.1016/j.cmet.2007.10.002. Review.

28.

Identification of rare Epstein-Barr virus infected memory B cells and plasma cells in non-monomorphic post-transplant lymphoproliferative disorders and the signature of viral signaling.

Shaknovich R, Basso K, Bhagat G, Mansukhani M, Hatzivassiliou G, Murty VV, Buettner M, Niedobitek G, Alobeid B, Cattoretti G.

Haematologica. 2006 Oct;91(10):1313-20.

29.

How do cancer cells acquire the fuel needed to support cell growth?

Thompson CB, Bauer DE, Lum JJ, Hatzivassiliou G, Zong WX, Zhao F, Ditsworth D, Buzzai M, Lindsten T.

Cold Spring Harb Symp Quant Biol. 2005;70:357-62.

PMID:
16869772
30.

ATP citrate lyase inhibition can suppress tumor cell growth.

Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D, Hingorani SR, Tuveson DA, Thompson CB.

Cancer Cell. 2005 Oct;8(4):311-21.

31.

ATP citrate lyase is an important component of cell growth and transformation.

Bauer DE, Hatzivassiliou G, Zhao F, Andreadis C, Thompson CB.

Oncogene. 2005 Sep 15;24(41):6314-22.

PMID:
16007201
32.

The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation.

Buzzai M, Bauer DE, Jones RG, Deberardinis RJ, Hatzivassiliou G, Elstrom RL, Thompson CB.

Oncogene. 2005 Jun 16;24(26):4165-73.

PMID:
15806154
33.

Expression of the IRTA1 receptor identifies intraepithelial and subepithelial marginal zone B cells of the mucosa-associated lymphoid tissue (MALT).

Falini B, Tiacci E, Pucciarini A, Bigerna B, Kurth J, Hatzivassiliou G, Droetto S, Galletti BV, Gambacorta M, Orazi A, Pasqualucci L, Miller I, Kuppers R, Dalla-Favera R, Cattoretti G.

Blood. 2003 Nov 15;102(10):3684-92. Epub 2003 Jul 24.

34.

Bax and Bak can localize to the endoplasmic reticulum to initiate apoptosis.

Zong WX, Li C, Hatzivassiliou G, Lindsten T, Yu QC, Yuan J, Thompson CB.

J Cell Biol. 2003 Jul 7;162(1):59-69.

35.

IRTAs: a new family of immunoglobulinlike receptors differentially expressed in B cells.

Miller I, Hatzivassiliou G, Cattoretti G, Mendelsohn C, Dalla-Favera R.

Blood. 2002 Apr 15;99(8):2662-9.

36.

IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy.

Hatzivassiliou G, Miller I, Takizawa J, Palanisamy N, Rao PH, Iida S, Tagawa S, Taniwaki M, Russo J, Neri A, Cattoretti G, Clynes R, Mendelsohn C, Chaganti RS, Dalla-Favera R.

Immunity. 2001 Mar;14(3):277-89.

37.

Safety-modified episomal vectors for human gene therapy.

Cooper MJ, Lippa M, Payne JM, Hatzivassiliou G, Reifenberg E, Fayazi B, Perales JC, Morrison LJ, Templeton D, Piekarz RL, Tan J.

Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6450-5.

38.

A rapid, PCR-based assay for episomal replication.

Cooper MJ, Hatzivassiliou G, Miron S.

Biotechniques. 1994 Jan;16(1):20-2, 24. No abstract available.

PMID:
8136130
39.

p53 mutations in bladder carcinoma cell lines.

Cooper MJ, Haluschak JJ, Johnson D, Schwartz S, Morrison LJ, Lippa M, Hatzivassiliou G, Tan J.

Oncol Res. 1994;6(12):569-79.

PMID:
7787250

Supplemental Content

Loading ...
Support Center